Trial reportBMC psychiatry2026
Baduanjin combined with computerized cognitive remediation therapy for the treatment of schizophrenia : a 8-week randomized controlled trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSchizophrenia is a severe mental disorder characterized by complex clinical presentations and marked impairments in social and occupational functioning. While antipsychotic medications are effective in managing positive symptoms, their efficacy in addressing negative symptoms, cognitive deficits, and overall improvements in social functioning and quality of life remains substantially limited.This study aims to evaluate the effects of Baduanjin combined with Computerized Cognitive Remediation Therapy (CCRT) on patients with schizophrenia, thereby contributing to the evidence base for its clinical management.
methodsA total of 120 hospitalized patients with schizophrenia (aged 29-64 years; 66.67% male) were recruited and randomly allocated to either an intervention group (n = 60) or a control group (n = 60). Participants in the intervention group received a combined 85-minute session (45 min of CCRT plus 40 min of Baduanjin training) five times per week, whereas the control group received CCRT alone for the same duration. Assessments of psychiatric symptoms, cognitive function, social functioning, and quality of life were conducted at baseline and post-intervention.
resultsBaseline characteristics were comparable between the two groups for all outcome measures (P > 0.05). Following the 8-week intervention, within-group analyses showed significant improvements from baseline in The Neurobehavioral Cognitive Status Examination(NCSE), The Scale of Social Function in Psychosis Inpatients( SSPI), and The Schizophrenia Quality of Life Scale(SQLS) scores for both groups (all P < 0.05). In contrast, a statistically significant reduction in The Positive and Negative Syndrome Scale(PANSS) total scores was only observed in the intervention group (P < 0.05). Moreover, intergroup analysis revealed that the intervention group demonstrated significantly greater improvements across all outcome measures (NCSE, SSPI, SQLS, and PANSS) compared to the control group post-intervention (all P < 0.05).
conclusionPatients with schizophrenia showed significantly better overall efficacy with an 8-week combined treatment of Baduanjin and CCRT compared to CCRT alone, particularly in improving psychiatric symptoms (especially negative symptoms), enhancing cognitive function, restoring social functioning, and improving quality of life. CLINICAL TRIAL REGISTRATION INFORMATION: The study protocol of this investigator-initiated randomised controlled trial was formally registered with the ISRCTN registry (registration number: ISRCTN14037337) on 12 May 2026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.